The world of drug discovery is witnessing a seismic shift as researchers and institutions move away from traditional animal models toward innovative human-based in vitro systems, driven by a pressing need to address the staggering failure rate of drug candidates in clinical trials, which exceeds
Imagine a world where chronic diseases like cardiovascular disorders, metabolic conditions, and autoimmune issues are treated not by altering the very fabric of DNA, but by subtly tweaking how genes are expressed—a safer, more precise approach to healing that could transform countless lives.
What happens when a pharmaceutical giant like Sanofi, a titan in the industry, unveils a drug that ticks all the clinical boxes yet leaves the market unimpressed? This is the perplexing reality surrounding Amlitelimab, an experimental treatment for eczema that promised to revolutionize patient care
In the ever-evolving landscape of pharmaceutical research, a staggering challenge persists: the need to uncover novel compounds that can tackle complex diseases with precision and efficacy, especially as resistance to existing drugs continues to grow. Scientists have long grappled with the
In a world grappling with the escalating burden of metabolic diseases, innovative solutions are urgently needed to address conditions like type 2 diabetes, obesity, non-alcoholic fatty liver disease, and certain cancers, which collectively affect millions globally and strain healthcare systems.
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of innovation in the industry. Today, we’re diving into the exciting developments surrounding Tryngolza, a groundbreaking lipid-lowering
